Business
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
- 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19 SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\n- 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020.\n\n“This quarter we drove strong performance through the continued growth of new prescribers with more patients benefitting from NUPLAZID® treatment for their Parkinson’s disease psychosis and remain on-track with our supplemental NDA for the treatment of dementia-related psychosis with a PDUFA date of April 3, 2021,” said Steve Davis, Acadia’s Chief Executive Officer. “We continue to advance our late-stage programs and invest in new opportunities through business development, highlighted by our recent acquisition of CerSci Therapeutics which expands our clinical pipeline with an innovative first-in-class, non-opioid, acute and chronic pain program.”\n\nCompany Updates\n\n\nNew clinical analyses across multiple studies of pimavanserin are being presented at this week’s 13th Clinical Trials on Alzheimer’s Disease (CTAD) meeting, including:\n\n\nOral presentation by Dr. Clive Ballard, University of Exeter Medical School: “Impact of Pimavanserin on Cognitive Measures in Patients with Neurodegenerative Disease: Results from 4 Placebo-Controlled Clinical Studies.”\n\n\nPoster presentation by Dr. Daniel Weintraub, Perelman School of Medicine at the University of Pennsylvania: “Impact of Pimavanserin Treatment on Motor Function in Patients with Neurodegenerative Disease: Results from 3 Clinical Studies.”\n\n\n\n\n\nIn October, Acadia announced a partnership with The Lewy Body Dementia Association (LBDA) on the release of a disease education adaptation of the new documentary Robin’s Wish©. The film is titled, “SPARK - Robin Williams and his Battle with Lewy Body Dementia©,” and will be available to academic research institutions and universities as part of educational programming for healthcare professionals.\n\n\n\nIn October, Acadia presented a poster titled “Healthcare Resource Utilization and Associated Costs for Dementia Patients with Psychosis: A Medicare Database Study,” at the Academy of Managed Care Pharmacy’s (AMCP) Nexus conference, and ...